[Vitamin D metabolism and osteoporosis in systemic sclerosis].

Szilvia Szamosi
Szilvia Szamosi
University of Debrecen
Zoltan Szekanecz
Zoltan Szekanecz
University of Debrecen Clinical Centre
United States

Orv Hetil 2017 Aug;158(32):1252-1258

Reumatológiai Tanszék, Debreceni Egyetem, Általános Orvostudományi Kar Debrecen, Nagyerdei krt. 98., 4032.

In the past few years more and more data have become available on the important role of vitamin D in immunological processes and inflammation. The role of vitamin D deficiency in the pathogenesis as well as in disease progression of different autoimmune and inflammatory conditions is suspected. Vitamin D deficiency is prevalent in several autoimmune diseases, including systemic sclerosis. Hypovitaminosis has been found to be associated with low bone mineral density and higher prevalence of osteoporosis in this group of patients. Determinants of low bone density in SSc are poorly understood. Studies have shown the importance of both traditional osteoporotic as well as disease-specific factors (extent of skin involvement, presence of internal organ manifestation, malabsorption, systemic sclerosis subtype, serological profile, medication) in the development of low bone mineral density. The relationship between low bone density in systemic sclerosis patients and the above mentioned risk factors may be more complex and the real role of each factor is unclear. Yet very few studies reported clinically relevant low bone mass outcomes such as fracture risk assessment and fracture associated mortality in scleroderma. This review aims to synthesize data about the essential role of vitamin D in immune homeostasis as well as the prevalence of hypovitaminosis, low bone density, changes in bone turnover markers and presence of osteoporosis in scleroderma patients. Orv Hetil. 2017; 158(32): 1252-1258.

Download full-text PDF

http://dx.doi.org/10.1556/650.2017.30816DOI Listing
August 2017
8 Reads

Publication Analysis

Top Keywords

low bone
systemic sclerosis
role vitamin
bone density
bone mineral
vitamin deficiency
mineral density
well prevalence
skin involvement
homeostasis well
extent skin
immune homeostasis
malabsorption systemic
essential role
sclerosis subtype
manifestation malabsorption
organ manifestation

Similar Publications

Low bone density in systemic sclerosis. A systematic review.

J Rheumatol 2013 Nov 15;40(11):1881-90. Epub 2013 Sep 15.

From the Toronto Scleroderma Program, Division of Rheumatology, Department of Medicine, Mount Sinai Hospital; Osteoporosis Program, Toronto General Hospital; Division of Rheumatology, Department of Medicine, Toronto Western Hospital; and Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

Objective: The effect of systemic sclerosis (SSc) on bone density is not well understood. Through systematic review of the literature, the objectives of this study were to synthesize data about the prevalence of low bone mineral density (BMD), risk factors for low BMD, and occurrence of fracture and fracture-related mortality in SSc.

Methods: A search was conducted of MEDLINE (1948-2012), Evidence Based Medicine Reviews (1991-2012), EMBASE (1980-2012), and CINAHL (1981-2012). Read More

View Article
November 2013

Bone mass and vitamin D in patients with systemic sclerosis from two Spanish regions.

Clin Exp Rheumatol 2012 Nov-Dec;30(6):905-11. Epub 2012 Dec 17.

Autoimmune Systemic Disease Unit, Hospital Universitario San Cecilio, Granada, Spain.

Objectives: To study the bone mass in patients with scleroderma (SSc) from two different Spanish regions and to evaluate the prevalence of vitamin D deficiency and insufficiency in this population and its possible relation to bone mineral density (BMD).

Methods: Disease, bone mineral density related variables and vitamin D were collected from all patients. Statistical analysis was carried out using the SPSS 17 statistics software for Windows. Read More

View Article
March 2013

The relationship between vitamin D and parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis.

Bone 2004 Jul;35(1):312-9

Department Health Care of the Elderly, Queens Medical Centre, University Hospital, Nottingham NG7 2UH, UK.

It is evident from several studies that not all patients with hypovitaminosis D develop secondary hyperparathyroidism. What this means for bone biochemistry and bone mineral density (BMD) remains unclear. The aim of this study was to investigate the effects of hypovitaminosis D (defined as a 25OHD < or = 30 nmol/l) and patients with a blunted PTH response (defined arbitrarily as a PTH within the standard laboratory reference range in the presence of a 25OHD < or = 30 nmol/l) in comparison to patients with hypovitaminosis D and secondary hyperparathyroidism (defined arbitrarily as a PTH above the standard laboratory reference range in the presence of a 25OHD < or = 30 nmol/l) and vitamin D-replete subjects (25OHD > 30 nmol/l). Read More

View Article
July 2004

Relationship between Body Mass Composition, Bone Mineral Density, Skin Fibrosis and 25(OH) Vitamin D Serum Levels in Systemic Sclerosis.

PLoS One 2015 16;10(9):e0137912. Epub 2015 Sep 16.

Rheumatology Clinic, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.

A reduced bone mineral density (BMD) is observed in several rheumatic autoimmune diseases, including Systemic Sclerosis (SSc); nevertheless, data concerning the possible determinants of bone loss in this disease are not fully investigated. The aim of this study is to evaluate the relationship between BMD, body mass composition, skin sclerosis and serum Vitamin D levels in two subsets of SSc patients. 64 post-menopausal SSc patients, classified as limited cutaneous (lcSSc) or diffuse cutaneous (dcSSc) SSc, were studied. Read More

View Article
May 2016